CVT-301 for Parkinson's disease: dose and effect size issues

Affiliations

¹ Centre d'Investigation Clinique, Services de Neurologie et de Pharmacologie Clinique, Réseau NS-PARK/FCRIN et Centre COEN NeuroToul, Centre Hospitalier Universitaire de Toulouse, Institut National de la Santé et de la Recherche Médicale, University of Toulouse, 31300 Toulouse, France. Electronic address: olivier.rascol@univ-tlse3.fr.

Comment

Olivier Rascol. Lancet Neurol. 2019 Feb.

. 2019 Feb;18(2):128-130.

doi: 10.1016/S1474-4422(18)30496-4.

¹ Centre d'Investigation Clinique, Services de Neurologie et de Pharmacologie Clinique, Réseau NS-PARK/FCRIN et Centre COEN NeuroToul, Centre Hospitalier Universitaire de Toulouse, Institut National de la Santé et de la Recherche Médicale, University of Toulouse, 31300 Toulouse, France. Electronic address: olivier.rascol@univ-tlse3.fr.

No abstract available

Comment on

Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.
LeWitt PA, Hauser RA, Pahwa R, Isaacson SH, Fernandez HH, Lew M, Saint-Hilaire M, Pourcher E, Lopez-Manzanares L, Waters C, Rudzínska M, Sedkov A, Batycky R, Oh C; SPAN-PD Study Investigators. LeWitt PA, et al. Lancet Neurol. 2019 Feb;18(2):145-154. doi: 10.1016/S1474-4422(18)30405-8. Lancet Neurol. 2019. PMID: 30663606 Clinical Trial.